Etoposide addition and brentuximab vedotin consolidation in first-line treatment of CD30-positive peripheral T-cell lymphoma: can we improve BV-CHP?

Lancet Haematol. 2024 Sep;11(9):e634-e636. doi: 10.1016/S2352-3026(24)00207-2. Epub 2024 Jul 24.

Authors

Edith Julia¹, Emmanuel Bachy²

Affiliations

¹ Hematology Department, Lyon Sud Hospital, Hospices Civils de Lyon, 69495 Piere Bénite, France; Lymphoma Immuno-Biology Research Unit, Inserm U1111, CIRI, Lyon, France.
² Hematology Department, Lyon Sud Hospital, Hospices Civils de Lyon, 69495 Piere Bénite, France; Lymphoma Immuno-Biology Research Unit, Inserm U1111, CIRI, Lyon, France. Electronic address: [email protected].

PMID: 39067466
DOI: 10.1016/S2352-3026(24)00207-2

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Brentuximab Vedotin* / therapeutic use
Consolidation Chemotherapy
Etoposide* / therapeutic use
Female
Humans
Ki-1 Antigen* / metabolism
Lymphoma, T-Cell, Peripheral* / drug therapy
Male
Middle Aged

Substances

Brentuximab Vedotin
Etoposide
Ki-1 Antigen